Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07631013 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Not yet
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT07631013: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT07631013 is a Phase 1 study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07631013, a Phase 1 study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a phase 1, single-arm, open-label, dose-escalation and dose-expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of TGFBR2 TROP2 CAR/IL15 NK cells in patients with high-risk oral premalignant lesions.
Interventions
- DRUG TROP2 CAR/IL-15 TGFBR2 KO NK cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2026-12-31 |
| Est. Completion | 2030-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07631013
The ClinicalTrials.gov registry entry for NCT07631013 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TROP2 CAR/IL-15 TGFBR2 KO NK cells is the first listed.
NCT07631013 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07631013 about?
NCT07631013 is a clinical study titled "Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions". This is a phase 1, single-arm, open-label, dose-escalation and dose-expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of TGFBR2 TROP2 CAR/IL15 NK cells in patients with high-risk oral premalignant lesions.
What is the current status of trial NCT07631013?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2026-12-31. Estimated completion is 2030-06-30.
What interventions are being tested in trial NCT07631013?
The interventions under investigation include: TROP2 CAR/IL-15 TGFBR2 KO NK cells (DRUG).
Who is sponsoring clinical trial NCT07631013?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.